LIXTE Biotechnology Holdings Provides Update on Recent Activities
20. Mai 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”Presentation at MedInvest Biotech and Pharma...